Interpace Biosciences Inc Debt/Equity
What is the Debt/Equity of Interpace Biosciences Inc?
The Debt/Equity of Interpace Biosciences Inc is 2.05
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on NASDAQ compared to Interpace Biosciences Inc
What does Interpace Biosciences Inc do?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Companies with debt/equity similar to Interpace Biosciences Inc
- Germ.Startups Grp Na O.N has Debt/Equity of 2.05
- MAN SE has Debt/Equity of 2.05
- Logic Instrument S.A has Debt/Equity of 2.05
- Jazz Pharmaceuticals plc has Debt/Equity of 2.05
- Archrock Inc has Debt/Equity of 2.05
- Telefonaktiebolaget LM Ericsson has Debt/Equity of 2.05
- Interpace Biosciences Inc has Debt/Equity of 2.05
- CIBT Education has Debt/Equity of 2.05
- Zeta Global has Debt/Equity of 2.05
- OMV AG has Debt/Equity of 2.05
- Premium Income has Debt/Equity of 2.05
- Pearl Polymers has Debt/Equity of 2.05
- Voltalia SA has Debt/Equity of 2.05